SCHEMBL23216815

SCHEMBL23216815

COc1ccc(C(OC[C@H]2O[C@@H](n3c(=O)[nH]c4c(NC(=O)c5ccccc5)ncnc43)[C@@H](O[Si](C)(C)C(C)(C)C)C2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 11/20 0.45
▸ BRD4 O60885 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA1 P30542 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23216911 1.00 TYMP (0.45) TYMPBRD4ADORA3ADORA1
SCHEMBL29709123 1.00 TYMP (0.45) TYMPBRD4ADORA3ADORA1
SCHEMBL29709063 1.00 TYMP (0.45) TYMPBRD4ADORA3ADORA1
SCHEMBL23215195 0.91 TYMP (0.53) TYMPBRD4ADORA1
SCHEMBL29709267 0.91 TYMP (0.53) TYMPBRD4ADORA1
SCHEMBL23023830 0.85 TYMP (0.46) TYMP
SCHEMBL18521074 0.85 TYMP (0.46) TYMP
SCHEMBL22381870 0.85 TYMP (0.46) TYMP
SCHEMBL18521315 0.85 TYMP (0.46) TYMP
SCHEMBL21305068 0.85 TYMP (0.55) TYMPADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2025-05-01 — — US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 — — US disclosed
US-20230392137-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-12-07 — — US disclosed
EP-4240849-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2023-09-13 — — EP disclosed
US-20230220384-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-07-13 — — US disclosed
WO-2023049477-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-03-30 — — WO disclosed
EP-4022059-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF Wave Life Sciences Ltd. (SG) 2022-07-06 — — EP disclosed
WO-2022099159-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-05-12 — — WO disclosed
WO-2021071858-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MECP2, ADAR, NSUN2 TYMP 1801/4885BRD4 1124/4885ADORA3 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback